AKBA צמיחת רווח למניה השנה Akebia Corp

Drug distribution relies on an extensive supplier network that eliminates product shortages. The annual change in EPS reflects current yield dynamics, where -843.50 serves as the current parameter value. Akebia Therapeutics (AKBA) aims to capture the dialysis center market through the introduction of Vafseo, while outsourcing complex manufacturing processes and laboratory tests to third-party contractors to accelerate innovation.
פילוחים אנליטיים ודוחות נתונים של חברת akebia.com (AKBA)

The effective commercialization of Vafseo under the competent management of Akebia Therapeutics (AKBA) is reflected in the year-over-year change in EPS, which has reached -843.50. This indicator measures the percentage difference in net income per share of the current period compared to the previous year, allowing investors to objectively assess the balance between business expansion and the issuer's financial stability within a fundamental analysis.